Celldex Therapeutics’ (CLDX) “Buy” Rating Reaffirmed at HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $64.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 106.45% from the stock’s previous close.

Several other equities analysts have also recently weighed in on CLDX. Canaccord Genuity Group lowered their price objective on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Guggenheim raised their target price on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. UBS Group upped their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.92.

Celldex Therapeutics Trading Down 4.9%

NASDAQ CLDX opened at $31.00 on Friday. The stock’s 50-day moving average price is $38.23 and its two-hundred day moving average price is $34.96. The company has a market cap of $2.43 billion, a PE ratio of -7.13 and a beta of 0.90. Celldex Therapeutics has a 1 year low of $22.10 and a 1 year high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.74 million. Research analysts forecast that Celldex Therapeutics will post -4.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLDX. Nykredit A S bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at approximately $67,000. Diversified Trust Co bought a new position in Celldex Therapeutics during the first quarter valued at approximately $223,000. Walleye Capital LLC acquired a new stake in Celldex Therapeutics in the first quarter valued at approximately $258,000. Amundi bought a new stake in Celldex Therapeutics in the first quarter worth approximately $297,000. Finally, Glenmede Trust Co. NA bought a new stake in Celldex Therapeutics in the first quarter worth approximately $357,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.